Takeda Pharmaceutical to Obtain Exclusive Right to Develop and Market Hematide.Tokyo, Japan, June 29, 2006 - (JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) ) - Takeda Pharmaceutical has signed a licensing agreement with US bio-venture company Affymax for Hematide, an agent for treating renal renal /re·nal/ (re´n'l) pertaining to the kidney. re·nal adj. Of or in the region of the kidneys. Renal Relating to the kidney. and malignant anemia malignant anemia n. See pernicious anemia. . Under the agreement, Takeda Pharmaceutical will receive exclusive rights to develop and sell Hematide worldwide, excluding Japan. Accordingly, Takeda Pharmaceutical will make an upfront payment of $105 million to Affymax. Further, Affymax will receive development and regulatory milestone payments of up to $280 million as well as commercial milestone payments of up to $430 million. Prior to this agreement, the two companies concluded a similar agreement regarding Japan in February 2006. Hematide, which was developed by Affymax, is a synthetic, peptide-based erythropoiesis-stimulating agent Erythropoiesis-stimulating agent, commonly abbreviated ESA, an agent similar to the that stimulates red blood cell production (erythropoeisis). ESAs, structurally and biologically, are similar to naturally occuring protein erythropoietin. . Currently, Affymax is conducting phase II clinical trials Noun 1. phase II clinical trial - a clinical trial on more persons than in phase I; intended to evaluate the efficacy of a treatment for the condition it is intended to treat; possible side effects are monitored phase II that cover patients with renal or malignant anemia. Copyright [c] 2006 Japan Corporate News Network. All rights reserved. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion